Randall Schommer
Joliet, United States
1567 RESULTS
Joliet, United States
PAPER Sciamanna G, Ponterio G, Tassone A, Maltese M, Madeo G, Martella G, Poli S, Schirinzi T, Bonsi P, Pisani A
PAPER Arsova A, Møller TC, Vedel L, Hansen JL, Foster SR, Gregory KJ, Bräuner-Osborne H
PAPER Bennett KA, Sergeev E, MacSweeney CP, Bakker G, Cooper AE
PAPER Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B
PAPER Wang WW, Zhang XR, Zhang ZR, Wang XS, Chen J, Chen SY, Xie CL
Bethesda, United States
Ph.D. studentLondon, United Kingdom
THERAPEUTICS 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine Addex Therapeutics ADX48621 Small Molecule Other Neurotransmitters Addex completed a Phase 2a trial for Parkinson’s Disease LID in 2012. Conducted in the U.S. and Europe, it enrolled 76 peopl
University Medical Center UtrechtUtrecht, Netherlands
Research Scholar, ICMR, IndiaShirpur, Dhule, India
University of MinnesotaMinneapolis
United States
Klinikum der Universität MünchenGermany